{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-072608","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.301678+00:00","generated_at":"2026-06-11T00:59:47.396775+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ABVC BioPharma regains Nasdaq compliance after equity-boosting transactions totaling ~$10.65M","bullets":["Company completed four transactions increasing stockholders' equity by ~$10.65M to meet Nasdaq listing requirement.","Issued 300K shares and 200K pre-funded warrants on July 31, raising $1.75M in equity.","Note conversion of $500K on Aug 1 added $0.5M; $308K note repayment via 176,678 shares added $1M more.","Agreed to acquire 20% of property from Zhonghui for 370K shares, expected to add $7.4M (closing pending).","Nasdaq will continue to monitor compliance; delisting risk remains if not maintained at next periodic report."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-072608","json":"https://secwatch.observer/filing/0001213900-23-072608.json","markdown":"https://secwatch.observer/filing/0001213900-23-072608.md","text":"https://secwatch.observer/filing/0001213900-23-072608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023072608/0001213900-23-072608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023072608/ea184468-8k_abvc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:59:47.396775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"050bca26a96a7df74fb09975584081dae7606d2c","claim":"ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding stockholders equity.","evidence_excerpt":"July 31, 2023, the Company issued 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share, in a registered direct offering. Pursuant to this transaction, the stockholders’ equity was increased by $1.75M. We also previously disclosed that on August 1, 2023, the holder of $500,000 of Notes (as hereinafter defined) converted such notes at $3.50 per share and received 142,857 shares of Common Stock. As a result of this conversion, the stockholders’ equity was increased by $0.5M. Additionally, as previ","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023072608/0001213900-23-072608-index.htm","confidence":0.82,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"stockholders equity"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}